Phio Pharmaceuticals Corp.
PHIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.38 | 0.01 | -0.00 | 0.03 |
| FCF Yield | -1.54% | -22.57% | -2,280,583.90% | -9.68% |
| EV / EBITDA | 0.00 | -0.21 | 7.51 | -5.25 |
| Quality | ||||
| ROIC | 0.00% | -22.87% | -15.38% | -35.44% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.87 | 1.17 | 0.72 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 17.73% | -99.14% | 6.92% | 29.75% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 4.67 | 7.51 | 3.22 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -19.69 | 0.00 | -650.57 |